CDK1 and breast carcinoma: Notably, several small molecule inhibitors aimed at CDK1 have progressed to clinical trials, highlighting the potential of CDK1 as a viable target for cancer treatment.[57] In this study, we conducted a comprehensive evaluation of CDK1 expression in breast cancer and its association with patient survival prognosis.